Tirzepatide: A "Twincretin" GameChanger?
CEimpact Podcast
English - July 04, 2022 09:00 - 23 minutes - 16.1 MBCourses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Curious about tirzepatide and what it means for patients? Tirzepatide, a combination GLP-1 and GIP agonist, was just approved by the Food and Drug Administration for the treatment of diabetes. Tirzepatide has also gained attention for its weight-reducing effects. However, how does tirzepatide compare to other GLP-1 agonists? Is tirzepaide a GameChanger for type 2 diabetes management? Learn more with host, Geoff Wall.
The GameChanger
Tirzepatide is the first in its class to hit the market and has been shown to be as or more effective than semaglutide in glycemic control and weight reduction.
Show Segments
00:00 – Introductions
01:15 – Type 2 Diabetes & Treatment
02:29 – Glucagon-like peptide-1 (GLP-1) Agonists
03:04 – Glucose-dependent insulinotropic polypeptide (GIP) Agonist
03:55 – Tirzepatide vs Semaglutide
14:27 - Tirzepatide vs Insulin
21:15 – Retinopathy & Financial Considerations
22:30 – Closing Remarks
Host
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
References and Resources
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Once-Weekly Tirzeaptide Versus Once-Daily Insulin Degludec as Add-On to Metformin With or Without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): A Randomized, Open-Label, Parallel-Group, Phase 3 Trial Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical TrialRedeem your CPE or CME here
CPE (Pharmacist) CME (Physician)Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Pharmacists: Get a membership Prescribers: Get a membershipCE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
Describe the safety and efficacy of tirzepatide compared to GLP-1 agonists Discuss the use of tirzepatide compared to basal insulin for blood glucose control Select a patient who may be a candidate for tirzepatide therapy0.05 CEU/0.5 Hr
UAN: 0107-0000-22-234-H01-P
Initial release date: 06/27/2022
Expiration date: 06/27/2023
Additional CPE and CME details can be found here.